Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

GE Healthcare Life Sciences to Create New US Headquarters

Published: Wednesday, August 20, 2014
Last Updated: Thursday, August 21, 2014
Bookmark and Share
When fully operational, the new facility will house more than 500 highly skilled employees and bring more than 220 new jobs to Massachusetts.

GE Healthcare Life Sciences announced today that it will open a new 160,000 square-foot facility in Marlborough, Massachusetts, as the new headquarters for its US operations. A $21M investment in the long-term future of this key GE Healthcare growth business, it will establish a new site for more than 500 GE Healthcare Life Sciences employees, including the creation of more than 220 new jobs in the US's leading life sciences and biotechnology cluster. Recruitment has begun with the site scheduled to open in Spring 2015, offering a dynamic working environment and career opportunities with a global leader in technology, science and business innovation.

“Our new facility in Massachusetts will position us for continued innovation and competition in such a fast-paced, innovative industry,” said Kieran Murphy, President and CEO of GE Healthcare Life Sciences. “We will be close to industry-leading talent, customers, and world-class academic and medical institutions across all the industry sectors we serve, from biotech and pharma, to diagnostics and medical devices.”

“Today, Massachusetts’ life sciences sectors are the fastest-growing sectors of our economy. We look forward to welcoming the U.S. life sciences headquarters of GE Healthcare and are pleased that the company will create a substantial number of new, STEM-related job opportunities in central Massachusetts,” said Governor Deval Patrick.

This investment will transform a currently unoccupied space into state-of-the-art labs, customer application facilities, and office space to complement GE Healthcare Life Sciences’ existing manufacturing capability in Westborough, Mass. The facility will consolidate GE Healthcare Life Sciences’ US East Coast presence, bringing together a critical mass of talent and expertise-dedicated collaboration, innovation and leadership in the industry. When fully operational, the new facility will bring more than 220 highly qualified new job opportunities to the area, including highly skilled positions such as lab technicians, biologists, medical doctors, process engineers, and customer service representatives.

GE Healthcare Life Sciences’ $4B business has more than 11,500 employees in over 100 countries, with the mission of enabling a new era of molecular and precision medicine. By providing customers with tools, insight and knowledge, GE Healthcare helps them accelerate the journey from biological understanding to clinical therapy. The new US headquarters will house employees from across the Life Sciences business, including its research, bioprocessing, medical imaging, in vitro diagnostics and services segments.

“Marlborough continues to be a center for innovation. This GE Healthcare Life Sciences investment, adding more than 220 new jobs with an exciting biotechnology leader, is proof that innovation is thriving outside Route 128, and of Marlborough’s ability to build the necessary infrastructure to attract top-tier, global life sciences companies,” said Mayor Arthur Vigeant.

“MassBIO continues to be engaged in policy, economic development and STEM education to foster the world’s leading biotech cluster. We are excited to continue work with industry leaders like GE Healthcare Life Sciences to promote innovation in the Greater Marlborough area,” said Robert Coughlin, President, MassBIO.

GE Healthcare Life Sciences has been actively supporting the development of new therapies for more than 60 years, with innovative technologies, services and solutions that enable the research, development, manufacture and use of the next generation of therapies. With technologies along the entire drug development, production and clinical continuum, GE helps scientists and physicians answer critical questions at every stage, from early research to patient diagnosis in the clinic.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

GE Healthcare Expands Single-Use Manufacturing Capabilities
The expanded site will manufacture a range of single-use products, including cell growth bags, based on a newly developed film platform resulting from GE’s strategic alliance with Sealed Air.
Friday, November 11, 2016
GE Healthcare Life Sciences Strengthens Business Resilience with ISO 22301
$100 million investment to double manufacturing capacity for chromatography media by 2018.
Saturday, December 05, 2015
GE Healthcare Life Sciences and Emerson Team Up
Collaboration will help drive improvements in productivity.
Saturday, November 28, 2015
GE Healthcare Life Sciences to Open Biopharmaceutical Technology and Training Laboratory in Turkey
Supports Turkey’s ambitions to expand domestic biopharmaceutical industry. Laboratory will be a key component of GE’s new Innovation Center in Istanbul.
Friday, November 14, 2014
GE Healthcare Life Sciences Named as Finalist for Four Bioprocess Industry Awards
Awards celebrate and recognize the outstanding people, organizations and technologies.
Saturday, October 04, 2014
GE Healthcare Appoints Emmanuel Ligner as General Manager
Emmanuel will oversee all worldwide commercial activities of Company's rapidly growing BioProcess business.
Friday, April 11, 2014
GE Healthcare to Build KUBio Factory for JHL Biotech in China
New factory to give JHL Biotech commercial biopharmaceutical manufacturing capabilities in Asia.
Thursday, September 26, 2013
GE Healthcare Life Sciences and Osaka University Team Up
Top four graduate students to be hosted at GE Healthcare Life Science’s Uppsala site.
Wednesday, August 21, 2013
GE Healthcare Life Sciences Completes Acquisition of Xcellerex, Inc.
Acquisition expands GE Healthcare’s offering of technologies and services for the manufacture of recombinant proteins, antibodies and vaccines.
Tuesday, May 15, 2012
Scientific News
More Effective Strategy for Producing Flu Vaccines
Researchers have developed a virus backbone, allowing producers to grow vaccine viruses in mammalian cells, rather than in eggs.
Improving Drug Production with Computer Model
A model has been developed that can be used to improve and accelerate the production of biotherapeutics, cancer drugs, and vaccines.
First New HIV Vaccine Study for Seven Years Begins
South Africa hosts historic clinical trial of experimental HIV vaccine aiming to safely prevent HIV infection.
Vaccination Against UTIs
Researchers have successfully vaccinated mice against E.coli growth in the bladder and kidneys.
First Steps to Neutralising Zika
Researchers have discovered a highly potent antibody that neutralises Zika infection at a cellular level.
Human Astrovirus Structure Could Lead to Therapies, Vaccines
Study shows where neutralizing antibody binds to human astrovirus, a leading cause of viral diarrhoea in children, elderly, and the immune-compromised.
Fighting Off HIV Infection Closer to Reality
Researchers have made significant progress in the development of a potential vaccine to protect against HIV infection.
Powerful New Tools to Combat Zika
Researchers have created a way to replicate the stucture of Zika virus, removing the genes that make the virus infectious.
More Immunotherapy Options Approved for Lung Cancer
The FDA has approved a new immunotherapy drug for certain patients with non-small cell lung cancer.
Dissecting Bacterial Infections at the Single-Cell Level
Researchers have used single-cell analysis technology to provide new insight into the Salmonella infection process.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!